News
According to results of an observational analysis, the efficacy of adalimumab is sustained in rheumatoid arthritis (RA) patients who continued therapy for 10 years. Biologic-naïve RA patients who had enrolled in the Corrona RA registry after initiating adalimumab during follow-up were included in...Learn More
News
by Ed Susman, Contributing Writer, MedPage Today ORLANDO -- Rheumatoid arthritis (RA) patients who received tocilizumab (Actemra) with methotrexate achieved low disease activity and could discontinue methotrexate while maintaining disease control, researchers said here. In a study designed to...Learn More
News
Healio Rheumatology, July 2017 With each passing year, big data has taken on a larger role in medicine and more specifically, in rheumatology. “Here is the thing about big data, it is not new. Health plans have been using big data for a long time,” Catherine MacLean, MD, PHD, from Hospital for...Learn More
News
Real-world evidence (RWE) is increasingly important to clinicians, regulators and payers Regional and local registries are a valuable source of RWE The large Corrona RA US registry has revealed information revenant to clinical practice (e.g. non-adhearance, effectiveness and safety of biologics,...Learn More
News
Corrona, a provider of U.S. disease registries, has enrolled the first patient in its novel inflammatory bowel disease (IBD) registry, launched in May 2017. This is the first national registry to collect data from patients with ulcerative colitis, Crohn’s disease and other IBDs. Corrona joined the...Learn More
News
SOUTHBOROUGH, Mass., June 1, 2017 /PRNewswire — Corrona, a nationwide provider of disease registries, announced that the first patient has been enrolled in its groundbreaking Inflammatory Bowel Disease (IBD) Registry. No national registry presently collects data from patients with inflammatory...Learn More